global psoriasis market with focus on plaque psoriasis: outlook to 2020 - new report by koncept...
TRANSCRIPT
Global Psoriasis Market Outlook to 2020 -----------------------------------------
2016
View Report Details
Executive Summary Psoriasis is a chronic inflammatory skin disease primarily causing scaling and inflammation of skin, characterized by
sharply demarcated, scaly, red skin lesions most often on the elbows, knees, scalps, hands and feet. It occurs when the body’s immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis has been majorly classified into Plaque psoriasis, Guttate psoriasis, Inverse psoriasis, Pustular psoriasis and Erytherodermic psoriasis. It is an autoimmune disease and may be triggered by smoking, alcohol consumption, cold or dry weather and stress.
In the wake of lesser treatment options and costly therapies, psoriasis remains as an under treated disease. Psoriasis treatment can be divided into three main groups: topical treatment, light therapy, and systemic medication based on the severity of the disease. The typical treatment options include TNF inhibitors and IL inhibitors. However, various therapies and drugs are in the pipeline and it is expected that treatment options will improve over time with higher efficacy and lower costs.
The global market for psoriasis has been increasing consistently over the last few years. The major factors contributing to the growth of the global psoriasis market are increasing smoking and alcohol consumption trends globally. Surging smoking population, increased spending on medicines, increasing sales of prescription drugs and escalating health care expenditure are the key growth drivers of the market. However, growth of the market is hindered by extensive drug development and approval process and side-effects associated with the existing medication for psoriasis.
Various treatment methods are readily used to control psoriasis in the US, such as TNFs, systemics and topicals. With relatively higher prevalence rates in the US, several companies are trying to grab larger market shares with their new and innovative drugs. Plaque psoriasis is a common form of this disease in the US with increasing prevalence each year.
The report “Global Psoriasis Market” analyzes the development of this market, with focus on the US treatment market. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Johnson and Johnson, Abbvie inc., Amgen Inc. and Novartis are being profiled along with their key financials and strategies for growth.
View Report Details
The global market for psoriasis has been increasing consistently over the last few years on account of increasing health awareness on part of patients and physicians…
In 2015, the revenue for global psoriasis market was recorded at US$... billion, increasing from US$... billion in 2014, reflecting an increase of ….% from the previous year.
By the end of 2025, it is estimated that IL-17 will occupy a major portion of the global psoriasis market with …% share and will be followed by anti-TNFs with …% share. Further, it is expected that Stelara will occupy …% share, followed by biosimilars with …%, Otelza with …% and new IL-23 with …% of the total market share
In 2015, Anti TNFs held …% share of the total market followed by Stelara with ...%, IL-17 with …% and Otelza with …% of the total market share, respectively.
Global Psoriasis Market by Therapy (2015)
Global Psoriasis Market by Value (2013-2017E)
Global Psoriasis Market by Therapy (2025E)
2013 2014 2015 2016E 2017E
Perc
enta
ge
US$
Billio
n
Revenue Annual Growth
Anti-TNFs Stelara IL-17 Otezla IL-17 Anti TNF Stelara Biosmilars Otelza IL-23
The patients undergoing treatment for psoriasis are exposed to the several severe side effects, including tuberculosis and leukoencephalopathy. This has subsequently led to the development of the new drugs with increased efficacy….
The prevalence of psoriasis in the US is expected to be … million by 2016 and is expected to reach … million by the end of 2020, rising at a CAGR of …% spanning 2016E-2020E. .
In 2015, TNFs lead the market by grabbing the maximum share amongst all treatments. It occupied …% share of the total psoriasis market generating revenue of US$.... million. It was followed by the IL-Mabs with …%, topicals with …%, systemics with …%, and Otezla with …% market share, respectively for the given period.
The US psoriasis market for IL-inhibitor drugs is expected to reach US$... million by the end of 2020 and is expected to grow at a CAGR of ….% for the period spanning 2016-2020.
The U.S. Psoriasis Market by Treatments (2015)
The U.S. Total Psoriasis Population (2016E-2020E)
The US Psoriasis Market by IL Inhibitors (2016E-2020E)
2016E 2017E 2018E 2019E 2020E
Millio
n
TNFs IL-Mabs Topicals Sytemics Otezla
2016E 2017E 2018E 2019E 2020ERevenue Patients Treated
US$
Milli
on
Thou
sand
s
In the US, with increasing prevalence of the plaque psoriasis, patients undergoing treatment are also expected to increase. The increase in market will largely be driven by introduction of several biosimilars as the patents of existing biologics will be expiring within next five years…
Patients undergoing treatment for plaque psoriasis will increase and reach … million by the end of year 2020 from expected … million patients in 2016 with fluctuating annual growth rate.
In 2015, among the biologics, Humira remained the most commonly used drugs and recorded the maximum revenue share of …%, followed by Stelara with …%, Enbrel with …%, Cosentyx with …% and Remicade with …% market share for the given year.
In 2015, Cosentyx generated maximum revenue per person with US$ …, followed by Enbrel with US$..., Stelara with US$... and Humira with US$..., respectively.
The US Plaque Psoriasis Biologics Market by Type (2015)
The US Plaque Psoriasis Patients On Treatment (2016E-2020E)
The US Annual Revenue Per Patient for Psoriasis Drugs (2015)
Humira
Stelara
Enbrel
Cosentyx
US$
2016E 2017E 2018E 2019E 2020EPatients On Treatment Annual Growth
Millio
n
Perc
enta
ge
Humira Stelara Enbrel Cosentyx Remaicade
Koncept AnalyticsCS-36, Second Floor, Ansal Plaza
Vaishali, Ghaziabad, U.P. – 201010
T. +91-120-4130959C: +91-9811715635
Contact Us:
www.konceptanalytics.com
Vikas GuptaBD Manager
These are abridged and sanitized sample pages from the comprehensive report on the “ Global Psoriasis Market ”. To know more about this report or for any customized research requirement, please contact the following:
View Report Details